SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (450)5/12/1999 4:22:00 PM
From: aknahow  Respond to of 712
 
I hear you, but I have trouble getting past the impediment of the closeness to Schering Plough. But, as posted previously, perhaps given CORR's 50% U.S./Canada share of the profits, this is not such a big problem. I have even more trouble understanding what is happening to CNTO than to CORR.



To: LLCF who wrote (450)5/12/1999 4:57:00 PM
From: Biomaven  Read Replies (1) | Respond to of 712
 
The J&J/CORR fit would be much worse than the J&J/CNTO fit, because of the stent connection for the latter.

Lots of biotechs have popped recently - don't think CORR's performance recently has been particularly unusual.

Peter



HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News